Granules India, one of the leading drug makers in India, is reportedly planning to invest $84 million in setting up new capacities, expanding existing ones and investing in R&D to improve its product mix in favour of higher value-added products. The project cost is proposed to be financed with debt of $68.5 million, including a corporate loan of up to $47.5 million from International Finance Corporation (IFC), and the rest through equity and internal accruals.
Granules India is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1938.85 |
| Dr. Reddys Labs. | 1269.80 |
| Cipla | 1441.70 |
| Zydus Lifesciences | 1159.85 |
| Lupin | 2502.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: